Japanese rapid/living recommendations on drug management for COVID‐19-Reference-Cited by-同舟云学术

Japanese rapid/living recommendations on drug management for COVID‐19

Published:2021-01 Issue:1 Volume:8 Page:
ISSN:2052-8817
Container-title:Acute Medicine & Surgery
language:en
Short-container-title:Acute Medicine & Surgery

Author:

Yamakawa Kazuma¹,Yamamoto Ryo²,Ishimaru Go³,Hashimoto Hideki⁴,Terayama Takero⁵,Hara Yoshitaka⁶,Hasegawa Daisuke⁶,Ishihara Tadashi⁷,Imura Haruki⁸,Okano Hiromu⁹,Narita Chihiro¹⁰,Mayumi Takuya¹¹,Yasuda Hideto¹²,Yamada Kohei¹³,Yamada Hiroyuki¹⁴,Kawasaki Tatsuya¹⁵,Shime Nobuaki¹⁶,Doi Kent¹⁷,Egi Moritoki¹⁸,Ogura Hiroshi¹⁹,Aihara Morio²⁰,Tanaka Hiroshi⁷,Nishida Osamu⁶,

Affiliation:

1. Department of Emergency Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan

2. Department of Emergency and Critical Care Medicine Keio University School of Medicine Tokyo Japan

3. Department of General Internal Medicine Soka Municipal Hospital Soka Japan

4. Department of Infectious Diseases The University of Tokyo Hospital Tokyo Japan

5. Department of Psychiatry School of Medicine National Defense Medical College Tokorozawa Japan

6. Department of Anesthesiology and Critical Care Medicine Fujita Health University School of Medicine Toyoake Japan

7. Department of Emergency and Critical Care Medicine Juntendo University Urayasu Hospital Urayasu Japan

8. Department of Infectious Diseases Rakuwakai Otowa Hospital/Department of Health Informatics School of Public Health Kyoto University Kyoto Japan

9. Department of Critical Care and Emergency Medicine National Hospital Organization Yokohama Medical Center Kanagawa Japan

10. Department of Emergency Medicine and Intensive Care Medicine Shizuoka General Hospital Shizuoka Japan

11. Department of Cardiovascular Medicine Graduate School of Medical Science Kanazawa University Kanazawa Japan

12. Department of Emergency and Critical Care Medicine Jichi Medical University Saitama Medical Center Saitama Japan

13. Department of Traumatology and Critical Care Medicine National Defense Medical College Tokorozawa Japan

14. Department of Primary Care and Emergency Medicine Kyoto University Hospital Kyoto Japan

15. Department of Pediatric Critical Care Shizuoka Children’s Hospital Shizuoka Japan

16. Department of Emergency and Critical Care Medicine Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan

17. Department of Acute Medicine The University of Tokyo Tokyo Japan

18. Division of Anesthesiology Department of Surgery Related Kobe University Graduate School of Medicine Kobe Japan

19. Department of Traumatology and Acute Critical Medicine Osaka University Medical School Suita Japan

20. Department of Gastroenterology and Hematology Graduate School of Medicine of Hirosaki University Hirosaki Japan

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ams2.664

Reference68 articles.

1. Development of rapid guidelines: 3. GIN-McMaster Guideline Development Checklist extension for rapid recommendations

2. Clinical Management of Patients with COVID‐19: A guide for front‐line healthcare workers.

3. RoB 2: a revised tool for assessing risk of bias in randomised trials

4. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is it possible to make ‘living’ guidelines? An evaluation of the Australian Living Stroke Guidelines;BMC Health Services Research;2024-04-03

2. Assessment of the efficacy and safety of favipiravir in patients with SARS-CoV-2 infection in United Arab Emirates: A single-center study;PHARM PRACT-GRANADA;2024

3. Real-world prescription of anti-COVID-19 drugs in hospitalized patients with COVID-19 in Japan;PLOS ONE;2024-01-26

4. Phenotypic changes in immune cells induced by granulocyte and monocyte adsorptive apheresis in patients with severe COVID‐19: An ex vivo study;Acute Medicine & Surgery;2024-01

5. Phase II, Double-Blinded, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy of Mebendazole in the Management of Symptomatic COVID-19 Patients;Pharmaceuticals;2023-05-29